VEPPANU is the first and only FDA-approved PROteolysis TArgeting Chimera (PROTAC). PROTACs are a new class of heterobifunctional protein degraders designed to harness the body's natural machinery to selectively degrade, rather than inhibit, disease-causing proteins. The recommended dosage of VEPPANU is 200 mg taken orally once daily. VEPPANU is immediately available through Rigel's network of specialty distributors and specialty pharmacies in the United States and Puerto Rico at $29,400 per 30-day supply.

"The commercial launch of VEPPANU marks an important milestone for Rigel and, more importantly, for patients living with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. In a pivotal trial, VEPPANU was generally well tolerated and demonstrated statistically significant and clinically meaningful improvement in progression-free survival versus fulvestrant in this patient population. As the first and only FDA-approved PROTAC, VEPPANU introduces a novel mechanism of action and represents an important new treatment option for healthcare providers to consider with their patients," said Raul Rodriguez, Rigel's president and CEO. "Supported by our established oncology infrastructure, experienced commercial and medical affairs teams and comprehensive patient support programs, we are well positioned to execute a successful commercial launch of VEPPANU, allowing Rigel to deliver for patients while advancing our long-term growth strategy."